Table 1.

Ongoing Cancer Clinical Trials Using DSF in the Treatment of Cancer

NCT Number	Year	Center	Tumor Type	Phase	Interventions	Recruitment
NCT0190716	2013	Washington University School of Medicine, United States;	•Glioblastoma	Early Phase I	Temozolomide + DSF/Copper gluconate	Active, not recruiting
NCT02715609	2016	•Washington University School of Medicine, United States; •University of Calgary, Canada;	•Glioblastoma Multiforme	•Phase I •Phase II	Surgery + Radiation + Temozolomide + DSF/Copper Gluconate	Recruiting
NCT0332334	2017	•University Hospital Olomouc, •The Institute of Molecular and Translational Medicine, Czech Republic;	•Breast Neoplasm Female •Metastatic Breast Cancer	Phase II	DSF	Recruiting
NCT0267897	2017	•St.Olavs University Hospital, Norway; •Sahlgrenska University Hospital, •Ryhov County Hospital, Sweden •Linköping University Hospital, •Lund University Hospital, •Karolinska University Hospital, •Uppsala University Hospital, •Örebro University Hospital, Sweden;	•Recurrent Glioma •Recurrent Glioblastoma	•Phase II •Phase III	DSF/Copper + Alkylating Agents	Recruiting
NCT02963051	2017	Duke University Medical Center, United States;	Prostate Cancer	Phase I	DSF/Copper gluconate	Recruiting
NCT0177791	2017	•Olympion Medical Center, •University of; Ioannina, Greece; •University of Eastern Finland; •University of Ulm, German;	Glioblastoma Multiforme	Phase II	Temozolomide and DSF/Copper	Not yet recruiting
NCT0303413	2017	•Beaumont Hospital, •Washington University School of Medicine, •John Theurer Cancer Center, •Lenox Hill Hospital, •University of Cincinnati, •Vanderbilt Ingram Cancer Center, •Baylor University Medical Center, •Huntsman Cancer Institute, United States;	Recurrent Glioblastoma	Phase II	DSF/Copper	Recruiting
NCT0315177	2017	Sahlgrenska University Hospital, Sweden;	Glioblastoma	Phase I	DSF versus Metformin	Not yet recruiting
NCT0336365	2018	Aurora St. Luke’s Medical Center, United States;	Glioblastoma/Glioblastoma Multiforme	Phase II	DSF/Copper gluconate + Temozolomide	Not yet recruiting